Delta Pharma, Inc., Ripley, MS

Is Delta Pharma, Inc. registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Delta Pharma, Inc. in Ripley, MS, first registered Aug 6, 2014 and most recently registered Dec 31, 2025.

Does Delta Pharma, Inc. hold a Mississippi pharmacy license?

State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.

Has Delta Pharma, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jul 29, 2025) for Delta Pharma, Inc. State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Delta Pharma, Inc.
Location
Ripley, MS
Type as FDA labels it
503B
FDA 503B list
Listed as Delta Pharma, Inc.
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
0
Latest action on that page
Nov 21, 2025
FDA Data Dashboard inspections
6 inspections: 4 OAI, 2 VAI; 7 published Form 483s
Form 483 text on this page
5 Form 483s, 20 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Delta Pharma, Inc., a 503B facility, with 5 dated actions.

Document
Nov 21, 2025Form 483483 Issued 11/21/2025fda.gov
Jul 29, 2025FMD-145 letterFMD-145 Letter Issued 07/29/2025Not linked by FDA
Apr 12, 2024Form 483483 Issued 04/12/2024FDA copy (archived)
Jun 2, 2023Form 483483 Issued 06/02/2023FDA copy (archived)
May 20, 2022Form 483483 Issued 05/20/2022fda.gov

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Delta Pharma, Inc., Ripley, MS (FEI number 3004034796), matched to this page by exact name, city and state. It lists 6 inspections: 4 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 2, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30040347961206930
May 20, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30040347961169898
Feb 23, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30040347961004804
May 24, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004034796971348
Oct 2, 2013Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004034796851435
Sep 17, 2010Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004034796682925

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 20 numbered observations in all, across 5 inspections ending Jun 8, 2018 to Nov 21, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Nov 10, 2025 to Nov 21, 2025: 2 observations

Firm on the cover
Delta Pharma, Inc., 114 W Mulberry St, Ripley, MS 38663-1709
FEI number
3004034796
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l0)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically, the semaglutide finished product primary labels for batches 05-0325-001, 05-0425-001, 05-0525-001, 05-0525-002, and 05-0525-003, do not include the following information: Address of your firm, and the statements "NOT FOR RESALE" and "OFFICE USE ONLY".

Material System

Observation 2

Approved components are not retested or reexamined as appropriate for identity, strength, quality and purity after storage for long periods with subsequent approval or rejection by the quality control unit.

Specifically, the raw material, Sterile water for Injection, USP, lot <Redacted B4>, expiration date 31March2025, was used in the production of the finished product, Semaglutide 2.5mg/mL, product batch 02-0225-001, expiration date 02 April 2025. The lot produced <Redacted B4> vials which were distributed for commercial use.

Inspection Apr 9, 2024 to Apr 12, 2024: 3 observations

Firm on the cover
Delta Pharma, Inc., 114 W Mulberry St, Ripley, MS 38663-1709
Establishment type on the cover
Outsourcing Facility Tbis document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
FDA district office on the cover
DISTRICT ADDRESS ANOD PHONE NUMBER 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
firm name, city and state on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.

SpecificalIy, your firm has no written procedures for performing a supplemental visual inspection of drug products where the drug products and/or the container closure system permits limited inspection of the contents. Your firm fills Brompheniramine Maleate 10 mg/ml sterile injectable into <Redacted B4> vials. Lot # <Redacted B4> was compounded and <Redacted B4> on September 19, 2023 and filled on September 20, 2023. The lot was released for distribution on November 14, 2023.

Observation 2

Written procedures are not followed for the sampling and testing of components.

Specifically, on May 31 , 2022 your firm received <Redacted B4> of Brompheniramine Maleate, USP API and assigned it Raw Material Receiving # <Redacted B4>. On February 7, 2022, your received in <Redacted B4> of Brompheniramine Maleate, USP API and assigned it Raw Material Receiving # <Redacted B4>. While they were the same vendor lot number, they were received in different shipments almost four (4) months apart. Your firm used the test results for the product received under Raw Material Receiving # <Redacted B4>, including identity, assay, loss on drying, and microbial limits testing to release the product received under Raw Material Receiving #. <Redacted B4>. The Brompheniramine Maleate, USP API received under Raw Material Receiving <Redacted B4> was then used to manufacture lot <Redacted B4> of Brompheniramine Maleate 10 mg/ml sterile injectable that was compounded and <Redacted B4> on September 19, 2023 and filled on September 20, 2023. The lot was released for distribution on November 14, 2023.

Observation 3

Representative samples are not taken of each shipment of each lot of components for testing or examination .

Specifically, GMP-SOP-0024 Receipt, Evaluation. and Dispositioning of Materials, revision 3 effective July 20, 2021, does not define a statistically sound sampling plan for raw materials (APls and excipients) when more than one container is received in for a lot/batch . For example, on February 7, 2022, your received in <Redacted B4> of Brompheniramine Maleate, USP API and assigned it Raw Material Receiving # <Redacted B4> your firm sent <Redacted B4> containers to your contract testing laboratory for testing .

Inspection May 22, 2023 to Jun 2, 2023: 1 observation

Firm on the cover
Delta Pharma, Inc., 114 W Mulberry St, Ripley, MS 38663-1709
FEI number
3004034796
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm failed to perform environmental monitoring (EM) sampling (viable and non -viable) in the ISO 7 room during the media fill on 5/26/2023. Because of the absence of EM sampling, the firm lacks the assurance of control of the ISO 7 room. Further, your firm’s media fill is not representative of your established drug production process where EM samples of the ISO 7 room are collected no less than (NLT) one time during filling.

Inspection May 10, 2022 to May 20, 2022: 5 observations

Firm on the cover
Delta Pharma, Inc., 114 W Mulberry St, Ripley, MS 38663-1709
FEI number
3004034796
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
4 04 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically, your fnm's location for gowning prior to entering the corridor that leads to the anteroom and classified areas is inadequate to minimize contamination of the Room 3 (anteroom) and Room 2 (ISO 8). Currently, face masks, head-beard cover, gloves, shoe covers, and gown are donned in the hallway (a non-classified, non-controlled area) prior to entering the corridor (a non-classified, controlled area). The same shoe covers are worn in the Room 3 and Room 2. Personnel may choose to wear dedicated-scrubs in lieu of a gown; however, the dedicated-scrubs are worn in Room 2, Room 3, the corridor, the gowning hallway, and other areas in the facility. We observed personnel in dedicated-scrubs leaving the corridor to retrieve additional materials during operations.

This is a repeat observation from FDA inspections ending on 10/02/2013, 05/24/2016, and 02/23/2017.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

According to GMP-SOP-0026, your stated contact disinfectant time for <Redacted B4> is 10 minutes, which is in alignment with the cleaning efficacy study performed under protocol P2671. However, this dwell time contradicts the established sporicidal contact time of 30 minutes, set for forth by the manufacturer.

Observation 3

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

Specifically, during the media fill run on 05/18/2022, the bag of sterile rubber stoppers was oriented in such a position inside the ISO-5 laminar hood where the opened end of the bag was not exposed to first-pass air.

Observation 4

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specificallv. your PIII'll

111111. On 05/16/2022. vour media fill rnn vielded the following three consecutive failures for the

automated P""' I: P""' I. There is no info1mation given in the procedure that would elaborate on the conditions for which a filter failure can be repeat tested, such as a decision-making tool. For example, the current procedure states that after a second failed attempt, an incident report is opened, and a third attempt may be perfo1med. But there is no explanation why this third attempt should be perfo1med. Ultimately the current procedure does not explain the justification on how a final passing result invalidates the the first two successive negative test results, or whether a third attempt failure will ultimately deem theP"III Ias compromised.

In addition, GMP-SOP-0030, Revision 03, does not require the documentation of a gross leak failure. The automated <Redacted B4> does not print a report for gross leak failures, and there is no log ( or equivalent) of such occurrences. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your environmental monitoring procedure (SOP-GMP-0042, Revision 04) for the ISO-5 area includes the use of viable air apparatus that samples 6000L of air in <Redacted B4> increments. Plates are changed after, <Redacted B4> sample is collected. You were unable to provide a qualification study, or equivalent, showing that the TSA plates used can sustain viability after the prolonged sample collection.

This is a repeat observation from 05/24/2014 and 02/23/2017.

Inspection dated Jun 8, 2018 by FDA (dates on the form not read): 9 observations

Firm on the cover
Delta Pharma, Inc., 114 West Mulberry St., Ripley, MS 38663
FEI number
3004034796
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
Nashville, TN 37217; 615-366-780 I Industry Information: www.fda.gov/oc/industry
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

Specifically, 1. Your firm receives non-sterile REDACTED B4 for use in the production of finished injectable drug products. You REDACTED B4; however, you have not performed any testing or validation to determine if REDACTED B4 is acceptable, and if so REDACTED B4. Also, you do not have a specific procedure for cleaning the REDACTED B4 after use.

2. Per the firm's SOP, media fills will be performed every REDACTED B4. Media fills have not been performed by REDACTED B4 operators who perform aseptic operations. One employee conducted a media fill on REDACTED B4; however, it did not simulate the firm's actual processes.

3. Sterilization REDACTED B4 for your REDACTED B4 have not been validated. Your firm uses the REDACTED B4 to REDACTED B4 finished injectable products and to sterilize stoppers, vials, and tubing for use in the production of finished injectable products.

4. Depyrogenation processes using an REDACTED B4 have not been validated. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, 1. Personnel monitoring is not performed for each production of injectable drug product.

[GJIIJIII

2. Viable air monitoring was not performed during the initial clean room certification dated REDACTED B 4 or during the two· following certifications dated REDACTED B4.

3. Your firm has not established microbial limits for environmental monitoring in your ISO 5 laminar flow hood, buffer room, or ante room.

4. Your firm does not perform positive or negative 'controls for environmental microbial testing.

**This is a repeat observation from FDA inspection ending 10/02/2013**

Observation 3

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specifically, There are no written procedures or records which demonstrate the following equipment has been calibrated: 1. The REDACTED B4 used for the REDACTED B4.

2. The REDACTED B4 thermometer in the incubator used for the incubation of environmental monitoring samples.

3. REDACTED B4 thermometers located in the refrigerator used for environmental media storage and in refrigerator used for storage of finished product that requires refrigeration. tbe

4. Scales used in weighing out ingredients for sterile processing.

5. The pH meter used to test the finished product before being filled into glass vials.

**This is a repeat observation from FDA inspections ending on 09/17/2010 and 10/02/2013**

Observation 4

Testing and release of drug product for distribution do ·not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically, Your firm adds preservatives to all products produced. You have not performed any testing to ensure the preservatives you add to your multi-dose vials remains effective through your expiration date.

Observation 5

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, Your firm sterilizes glassware and containers/closures on site. The mixing glassware is stored in the REDACTED B4 room and the containers/closures for finished injectable product are stored in the ante room. Both are stored still REDACTED B4. You have not conducted hold time studies for glassware or containers/closures to determine how long these can be stored and still remain sterile for use .

Observation 6

Batch production and control records do not include complete information relating to the production and control of each batch.

Specifically, Your firm's batch records lack the following information: 1. The individual who performs each step in the processing does not sign off on the batch record. Th e REDACTED B4 however, the firm's REDACTED B4 performs these processi ng steps.

2. On processing steps where a time limit is established, start and stop times are not recorded to ensure the time limit was met. Also, on steps that require heating, no temperature range is defined.

3. The batch production record states the theoretical and actual yield; however, the percentage of yield is not calculated and an acceptable range is not identified.

Observation 7

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically, your firm's gowning requirements for personnel involved in the processing of sterile drug products do not include forehead or eye covers.

Observation 8

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm does not have a written stability protocol and stability testing that has been performed did not include stability indicating tests such as impurities and degradents.

Observation 9

The labels of your outsourcing facility's drug products does not include information required bysections 503B(a) (10)(A) and (B).

Specifically, the following information is not found on your drug product labeling:

The statements, "This is a compounded drug" and the date the drug was compounded, are not on your drug product labels.

Examples of drug products that do not contain this information: Dexamethasone Acetate Suspension, USP 8mg/ml; Betasone SA-6 6mg/ml; Benadram SA-6 6mg/ml; Delta MP-100 100mg/ml

In addition, information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1 088. Examples of drug products that do not contain this information: Deltalone-40 40mg/ml; Betasone 3mg/ml; Bromphed 10mg/ml; Prometh 50mglml

Further, the route of administration is not present on one of your outsourcing facility's drug product label. Betasone 3mg/ml

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Mississippi are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.

FDA’s 503B list

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Delta Pharma INC”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
71791-0200SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.